KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Finished Goods: 2016-2024

Historic Finished Goods for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Dec 2024 value amounting to $20.5 million.

  • Acadia Pharmaceuticals' Finished Goods rose 30.84% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 30.84%. This contributed to the annual value of $20.5 million for FY2024, which is 309.14% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Finished Goods stood at $20.5 million, which was up 309.14% from $5.0 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Finished Goods registered a high of $20.5 million during FY2024, and its lowest value of $1.1 million during FY2021.
  • For the 3-year period, Acadia Pharmaceuticals' Finished Goods averaged around $9.1 million, with its median value being $5.0 million (2023).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Finished Goods plummeted by 54.24% in 2020, and later soared by 309.14% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Finished Goods (Yearly) stood at $1.5 million in 2020, then fell by 23.33% to $1.1 million in 2021, then surged by 72.89% to $1.9 million in 2022, then skyrocketed by 159.66% to $5.0 million in 2023, then spiked by 309.14% to $20.5 million in 2024.